Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925203 | 0.84 | HSP90AA1 (0.61) | ALOX5HPGDKDM4EALDH1A1HIF1A | |
| SCHEMBL3389986 | 0.82 | HPGD (0.57) | HPGDKDM4EALDH1A1HIF1AMEN1 | |
| SCHEMBL12459658 | 0.80 | CA2 (0.52) | HPGDKDM4EALDH1A1HIF1AALOX15 | |
| SCHEMBL27382845 | 0.79 | ADORA2A (0.62) | KDR | |
| SCHEMBL4924107 | 0.78 | NR1H4 (0.48) | ALOX5KDM4EALDH1A1MEN1CASP1 | |
| SCHEMBL1977469 | 0.76 | ALOX5 (0.61) | ALOX5HPGDKDM4EALDH1A1HIF1A | |
| SCHEMBL4928709 | 0.75 | SYK (0.58) | HPGDKDM4EALDH1A1HIF1AALOX15 | |
| SCHEMBL4925865 | 0.75 | KMT2A (0.54) | ALOX5HPGDKDM4EALDH1A1HIF1A | |
| SCHEMBL17774862 | 0.75 | ALOX5 (0.55) | ALOX5HPGDKDM4EALDH1A1HIF1A | |
| SCHEMBL17774860 | 0.75 | KDM4E (0.58) | ALOX5HPGDKDM4EALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| JP-2008508348-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | claimed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | claimed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | claimed |
| US-10576148-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2020-03-03 | — | — | US | disclosed |
| US-20180071388-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2018-03-15 | — | — | US | disclosed |
| US-9872822-B2 | Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition | L'OREAL (FR) | 2018-01-23 | — | — | US | disclosed |
| US-9872822-B2 | Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition | L'OREAL (FR) | 2018-01-23 | — | — | US | disclosed |
| EP-2475387-B1 | VAP-1 INHIBITORS FOR USE IN TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP (FI) | 2017-11-01 | — | — | EP | disclosed |
| US-9795671-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2017-10-24 | — | — | US | disclosed |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | ALOX5 533/4885NOX4 84/4885HPGD 3242/4885 |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | KRT18, ARSA, SQOR | ALOX5 195/4885NOX4 345/4885HPGD 588/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | ALOX5 557/4885NOX4 68/4885HPGD 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.